readthroughSign in
Nov 12, 2026Publication

Lakefront posts nine-month 2026 profit, advances gamgertamig and cuts GLPG3667

Lakefront Biotherapeutics swung to a nine-month net profit, sold its early-stage cell therapy pipeline, and guided to at least €2 billion in year-end cash.

Lakefront Biotherapeutics NV reported financial results for the first nine months of 2026 and provided a business update on November 11, 2026. The company posted a net profit of €13.9 million for the period, compared with a net loss of €461.3 million in the same period of 2025.1 Total net revenues fell to €26.1 million from €211.4 million a year earlier, largely because the prior year included €172.6 million tied to Gilead's exclusive access rights to Lakefront's drug discovery platform, income that was fully recognized by the end of 2025.1

On the pipeline side, a poster on gamgertamig data from ongoing Phase 1b studies in autoimmune cytopenias was accepted for the 2026 American Society of Hematology meeting, with an investor webcast set for December 14, 2026.1 The FDA granted gamgertamig Orphan Drug Designation for pemphigus, adding to earlier Fast Track and Orphan Drug designations for autoimmune hemolytic anemia and immune thrombocytopenia.1 Gamgertamig is expected to enter registrational studies in 2027.1 Separately, Lakefront decided to discontinue its GLPG3667 program after reviewing the competitive landscape and holding discussions with potential strategic partners, with the discontinuation cost not expected to be material.1

On corporate transactions, Lakefront on October 14, 2026 sold its next-generation early-stage cell therapy pipeline to Armed Cell Therapeutics BV in exchange for €8 million upfront, up to $230 million in milestones and a low-single-digit royalty; the program originated from AboundBio, acquired by the company (then Galapagos NV) in 2022.1 The company also completed a €50 million share buyback on October 16, 2026, repurchasing 1.99 million shares at an average €25.19.1 A second €50 million repurchase program has been approved and is expected to complete by the end of the first quarter of 2027.1 For year-end 2026, Lakefront expects cash and financial investments between €2.0 billion and €2.05 billion.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.